A second PARP inhibitor, talazoparib, has been recently approved for the treatment of germline BRCA1/2-associated metastatic breast cancer after the phase III EMBRACA trial (A Study Evaluating Talazoparib, a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients with BRCA Mutation) compared talazoparib alone with standard chemotherapy in the first-fourth line treatment setting.32 A PFS benefit was observed (HR 0.54, 95% CI 0.41–0.71, p < 0.001) in the talazoparib arm when compared with chemotherapy of provider choice. The gene discussed is BRCA1; the disease is breast cancer.